Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Dose Escalating Single Blind Study to Assess the Safety, Tolerability and Pharmacokinetics of a Single Dose of PRS-060 Administered by Oral Inhalation or IV Infusion in Healthy Subjects

Next Previous
X
Search
Trial Profile

A Dose Escalating Single Blind Study to Assess the Safety, Tolerability and Pharmacokinetics of a Single Dose of PRS-060 Administered by Oral Inhalation or IV Infusion in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 Oct 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elarekibep (Primary) ; Elarekibep (Primary) ; Elarekibep (Primary)
  • Indications Asthma
  • Focus Adverse reactions; First in man
  • Sponsors Pieris Pharmaceuticals

    • Most Recent Events

    • 01 Aug 2019 Results presented in the Pieris Pharmaceuticals media release.
    • 01 Aug 2019 According to a Pieris Pharmaceuticals media release, data from this trial were presented at the 2019 American Thoracic Society International Conference earlier this year.
    • 22 May 2019 According to a Pieris Pharmaceuticals media release, data will be presented at an upcoming medical meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top